This webinar will shed light on the entire process that takes place from the time the sponsor submits the initial IND to the FDA for initial 30-days. Alongside this presentation would detail the various grounds on which the FDA may consider placing a clinical hold. What’s more; the options/ ways to respond to the clinical hold is also discussed to help the sponsor effectively work toward the resolution on the clinical hold.
Course Objectives:
• Understanding each step and the associated process(es)s in greater detail helps the sponsor to improve the chances of success to start the clinical study
• The webinar will help the sponsor, or the company understand the FDA’s grounds on imposing clinical hold and also options for mitigating that risk
• In the event of a clinical hold; one can learn the options and ways to handle the same.
• Tips on the best practices for the dialogue between the Sponsor and the FDA during the initial submission phase would also help the sponsor plan and organize the submission of the initial IND to minimize delays or potential hold
Why Should You Attend:
It is important for the sponsor(s)/ Pharma companies to understand the process/ steps once the initial IND is submitted to the FDA. Understanding the rational for imposing the clinical trial hold is critical in order for the sponsor to avoid or mitigate this risk. Clinical hold not only delays the start of the clinical trial but also adds to the capital and other resources utilized for the clinical study.
Course Outline:
• Overview of the basic steps to the process for the initial 30 days after an initial IND is submitted to the FDA
• Understanding each step and the associated process(es)s in greater detail
• Definition and types of clinical hold
• Rational for imposing a clinical Trail hold for phase I by the FDA
• Identification and options for resolution of the clinical hold
• Analyzing the options for the sponsor’s response to clinical hold
• Understanding the differences in status between hold, inactive & Terminated
• Some tips on the best practices for the dialogue between the Sponsor and the FDA during the initial submission phase
• Quick glance at the IND application format
What You Get:
• Training Materials
• Live Q&A Session with the Speaker
• Participation Certificate
• Access to Signup Community (Optional)
• Reward Points
Who Will Benefit:
• The following professionals or disciplines will benefit from attending this Webinar:
• Regulatory affairs professionals
• Senior management executives (CEO, COO, CFO, etc)
• Drug discovery and development professionals (R&D and CMC)
• Intellectual property experts
• Project Managers and Clinical trial specialists
• Regulatory Compliance Associates and Managers
• People investing in FDA-regulated product development projects
6 Hours Virtual Seminar: Understanding and Controlling Biofilm - Preventing Water System Microbial Problems and Surviving Inspections
Get Instant Access 360 Minutes View Program |
Understanding Recent Advancements and Paradigms in Immunology
Get Instant Access 90 Minutes View Program |
Bioavailability and Bioequivalence Studies submitted in NDAs and INDs
Get Instant Access 90 Minutes View Program |
Veterinary Feed Directive (VFD) Final Rule – What you need to know?
Get Instant Access 60 Minutes View Program |
Packaging and Labeling for Commercial and Clinical Products
Get Instant Access 90 Minutes View Program |
Get Instant Access On-Demand Access
Preparing for the ICE Storm: What to Do During I 9 Audits and ICE Raids
Janette S. Levey
Human Resources
Get Instant Access On-Demand Access
OSHA Inspections and Investigations-How to Manage Them
Irwin Dobrushin
Environment Health and Safety | OSHA
Get Instant Access On-Demand Access
29 CFR 1904: OSHA's New Injury Recordkeeping E-Submission Rule
Occupational Safety and Health Administration
Get Instant Access On-Demand Access
Working with Excel Databases: Sort, Filter, Subtotal and More
Cathy Horwitz
Cross Industry | Skill Enhancement
Get Instant Access On-Demand Access
Writing Audit Reports
Jonnie T. Keith CIA, CFE, CGAP, CICA
Governance, Risk and Compliance
Get Instant Access On-Demand Access
BSA Reporting Requirements
Banking and Financial Services Industry
Get Instant Access On-Demand Access
Human Factors-Usability Based on ISO 62366
Medical Device | Diagnostic | Pharmaceutical | Biologics fields
Get Instant Access On-Demand Access
Chat GPT for Project Managers
Charles H. Paul
All FDA Regulated Industry